Form Bio Integrates AI and Wet Lab Validation for Gene Therapy Development

Form Bio announced it will present its integrated gene therapy development platform at the Cell & Gene Meeting on the Mesa in September 2026. The San Carlos, California-based company's solution connects AI-powered vector design with wet lab validation and manufacturing insights to address challenges earlier in the development pipeline.

Manufacturing challenges in gene therapy often emerge late in development, after a candidate has been selected, making modifications costly. Form Bio aims to incorporate manufacturability considerations earlier, allowing researchers to assess sequence and vector characteristics that impact production while designs are still adaptable.

"The industry has historically treated design and manufacturing as sequential but separate parts of development," said Form Bio CEO Michelle Chen. "We believe there is an opportunity to connect them much earlier. If you can identify manufacturing challenges while designing the AAV payload and vector sequence, you can make better-informed design decisions before they become costly downstream problems."

The company has expanded its platform to integrate computational design with experimental validation and manufacturing-focused insights. Its newly opened wet lab facility allows researchers to connect computational predictions with biological evidence. This "Lab in the Loop" approach creates a continuous feedback cycle where vector designs are experimentally evaluated, with results informing subsequent iterations.

Form Bio leadership will be present at the conference, with CEO Michelle Chen and other executives available to discuss their solutions. A presentation will focus on how design decisions influence manufacturing and how manufacturability, quality, and safety can be integrated earlier in the development process.